The new Covid-19 variant identified in South Africa can evade the antibodies that attack it in treatments using blood plasma from previously recovered patients, and may reduce the efficacy of the current line of vaccines, according to scientists.
Final results from Pfizer Inc.’s Covid-19 vaccine trial showed the company’s shot had a 95% success rate and two months of safety data, paving the way for the drugmaker to apply for an emergency U.S. authorization within days.
Johnson & Johnson secured more than $1 billion in additional funding for the company’s Covid-19 vaccine research through an expansion of J&J’s partnership with the Biomedical Advanced Research and Development Authority (BARDA), a division of the U.S. Department of Health and Human Services.
Pfizer Inc.’s experimental Covid-19 vaccine was more than 90% effective based on initial trial results, the company said, a major victory in the fight against a pandemic that has killed more than 1 million people and battered the world’s economy.
An AstraZeneca executive said he felt encouraged by “incredibly promising” large-scale Covid-19 vaccine trial results unveiled by New York-based Pfizer and the company’s German partner BioNTech.
ViiV Healthcare announces investigational injectable cabotegravir is superior to oral standard of care for HIV prevention in women Interim analysis from HPTN 084 study shows long-acting injectable cabotegravir administered every […]
Sanofi Hits the Brakes on Its Hemophilia Program Published: Nov. 6, 2020 By Mark Terry BioSpace Three hemophilia organizations, the World Federation of Hemophilia, the European Haemophilia Consortium and […]
In a Phase III study, the biologic Dupixent met primary and all key secondary endpoints in children ages 6 to 11 who have uncontrolled moderate-to-severe asthma.
Novartis said new interim data from an ongoing phase clinical trial for the company’s $2.1 million-per-patient gene therapy Zolgensma showed spinal muscular atrophy patients experienced significant therapeutic benefit.
Eli Lilly and Company announced positive results from CENTURION, the company’s Phase III study looking into Reyvow (lasmiditan) for migraine attacks.
